These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 207856)

  • 1. New opiate-receptor model.
    Kolb VM
    J Pharm Sci; 1978 Jul; 67(7):999-1002. PubMed ID: 207856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity studies of narcotic agonists and antagonists from quantum chemical calculations.
    Loew GH; Berkowitz DS; Burt SK
    NIDA Res Monogr; 1978; (22):278-316. PubMed ID: 213725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The opiate receptor: a model explaining structure-activity relationships of opiate agonists and antagonists.
    Feinberg AP; Creese I; Snyder SH
    Proc Natl Acad Sci U S A; 1976 Nov; 73(11):4215-9. PubMed ID: 186791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Irreversible opiate agonists and antagonists. II. Evidence against a bivalent mechanism of action for opiate azines and diacylhydrazones.
    Hahn EF; Nishimura S; Goodman RR; Pasternak GW
    J Pharmacol Exp Ther; 1985 Dec; 235(3):839-45. PubMed ID: 2416909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of addition of a 2-methyl group to ethyl nipecotates (beta-meperidines) on receptor affinities and opiate agonist/antagonist activities.
    Lawson JA; Cheng A; DeGraw J; Frenking G; Uyeno E; Toll L; Loew GH
    J Med Chem; 1988 Oct; 31(10):2015-21. PubMed ID: 2845084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effect of humoral endorphin on the binding of opiate agonists and antagonists.
    Sarne Y; Itzhak Y; Keren O
    Eur J Pharmacol; 1982 Jul; 81(2):227-35. PubMed ID: 6288405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantum chemical studies of N-substituent variation in the oxymorphone series of opiate narcotics.
    Loew GH; Berkowitz DS
    J Med Chem; 1978 Jan; 21(1):101-6. PubMed ID: 73588
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-substituent modulation of opiate agonist/antagonist activity in resolved 3-methyl-3-(m-hydroxyphenyl)piperidines.
    Cheng A; Uyeno E; Polgar W; Toll L; Lawson JA; DeGraw JI; Loew G; Camerman A; Camerman N
    J Med Chem; 1986 Apr; 29(4):531-7. PubMed ID: 3007760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-acting opiate agonists and antagonists: 14-hydroxydihydromorphinone hydrazones.
    Pasternak GW; Hahn EF
    J Med Chem; 1980 Jun; 23(6):674-6. PubMed ID: 6156240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-activity relationships for drugs binding to the agonist and antagonist states of the primary morphine receptor.
    Cheney BV
    J Med Chem; 1988 Mar; 31(3):521-31. PubMed ID: 2831361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irreversible opiate agonists and antagonists. III. Phenylhydrazone derivatives of naloxone and oxymorphone.
    Hahn EF; Itzhak Y; Nishimura S; Johnson N; Pasternak GW
    J Pharmacol Exp Ther; 1985 Dec; 235(3):846-50. PubMed ID: 2416910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opiate agonists and antagonists discriminated by receptor binding in brain.
    Pert CB; Pasternak G; Snyder SH
    Science; 1973 Dec; 182(4119):1359-61. PubMed ID: 4128222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydropmorphone].
    Ananthan S; Khare NK; Saini SK; Seitz LE; Bartlett JL; Davis P; Dersch CM; Porreca F; Rothman RB; Bilsky EJ
    J Med Chem; 2004 Mar; 47(6):1400-12. PubMed ID: 14998329
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular orbital calculations of proton transfer energetics in model systems: the interaction of opiate agonists and antagonists with opiate receptors.
    Bennett LK; Beamer RL
    J Pharm Sci; 1988 Nov; 77(11):986-90. PubMed ID: 2852247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of opiate agonist and antagonist receptor binding by protein modifying reagents.
    Wilson HA; Pasternak GW; Snyder SH
    Nature; 1975 Feb; 253(5491):448-50. PubMed ID: 46111
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of the opiate antagonists diprenorphine and naloxone and of selected opiate agonists on feeding behavior in guinea pigs.
    Billington CJ; Herman BH; Bartness TJ; Levine AS; Morley JE
    Life Sci; 1990; 46(2):147-54. PubMed ID: 2153888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actions of opiate antagonists with selective receptor interactions in hemorrhagic shock.
    Curtis MT; Lefer AM
    Circ Shock; 1983; 10(2):131-45. PubMed ID: 6301706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 7-spirobenzocyclohexyl derivatives of naltrexone, oxymorphone, and hydromorphone as selective opioid receptor ligands.
    Fang X; Larson DL; Portoghese PS
    J Med Chem; 1997 Sep; 40(19):3064-70. PubMed ID: 9301669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Receptor binding, antagonist, and withdrawal precipitating properties of opiate antagonists.
    Valentino RJ; Katz JL; Medzihradsky F; Woods JH
    Life Sci; 1983 Jun; 32(25):2887-96. PubMed ID: 6304445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of the mouse vas deferens to determine mu, delta, and kappa receptor affinities of opioid antagonists.
    Cohen ML; Mendelsohn LG; Mitch CH; Zimmerman DM
    Receptor; 1994; 4(1):43-53. PubMed ID: 8038706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.